Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline.

Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning, ...

Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...

Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor ...

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trialSTX-478 ...

Eli Lilly (LLY) agreed to acquire an experimental treatment for breast cancer and other advanced solid tumors from Scorpion Therapeutics for up to $2.5 billion. The purchase price includes an upfront ...

Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base. | ...

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...